PMID- 10838657
OWN - NLM
STAT- MEDLINE
DCOM- 20000816
LR  - 20191104
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 23
IP  - 3
DP  - 2000 May-Jun
TI  - Quantification of tumor-specific T lymphocytes with the ELISPOT assay.
PG  - 289-95
AB  - The characterization of tumor-associated antigens and of human leukocyte antigen 
      (HLA) class I molecule-binding peptide epitopes derived from these antigens has 
      prompted the initiation of various vaccination trials aimed at inducing 
      tumor-specific CD8+ T cells in persons with cancer. Sensitive and easy-to-perform 
      T-cell assays that assess the frequency of tumor-reactive T cells are crucial for 
      the evaluation and further development of vaccination approaches. This review 
      focuses on a novel ELISPOT technique that allows quantification of tumor-specific 
      T lymphocytes from peripheral blood by detecting antigen-induced cytokine 
      secretion. Various ELISPOT methods using different antigen-presenting cells and 
      different cytokines as read-out are described. T-cell analyses performed using 
      the standard chromium release assay and the ELISPOT assay are also compared. 
      Results from various clinical trials, including peptide and whole tumor cell 
      vaccination and cytokine treatment, are now available and show the suitability of 
      the ELISPOT assay for monitoring T-cell responses. To establish a basis for 
      standardization and to further improve this technique, the first comparative 
      quality assurance studies analyzing T-cell frequencies in different laboratories 
      with the ELISPOT assay are being performed.
FAU - Schmittel, A
AU  - Schmittel A
AD  - Universitatsklinikum Benjamin-Franklin, Medizinische Klinik III (Hamatologie, 
      Onkologie, and Transfusionsmedizin), Berlin, Germany.
FAU - Keilholz, U
AU  - Keilholz U
FAU - Thiel, E
AU  - Thiel E
FAU - Scheibenbogen, C
AU  - Scheibenbogen C
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Review
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0R0008Q3JB (Chromium)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/*immunology
MH  - Chromium
MH  - Cytokines/metabolism
MH  - Enzyme-Linked Immunosorbent Assay/*methods
MH  - Humans
MH  - Monitoring, Immunologic
MH  - Neoplasms/*immunology
MH  - Sensitivity and Specificity
MH  - T-Lymphocytes, Cytotoxic/*immunology/metabolism
RF  - 50
EDAT- 2000/06/06 09:00
MHDA- 2000/08/19 11:00
CRDT- 2000/06/06 09:00
PHST- 2000/06/06 09:00 [pubmed]
PHST- 2000/08/19 11:00 [medline]
PHST- 2000/06/06 09:00 [entrez]
AID - 10.1097/00002371-200005000-00001 [doi]
PST - ppublish
SO  - J Immunother. 2000 May-Jun;23(3):289-95. doi: 10.1097/00002371-200005000-00001.